+441518081136A retrospective chart review of Cranial Electrotherapy Stimulation for clients newly admitted to Residential Drug Treatment
2nd International Conference on Addiction Research and Therapy
May 13-14, 2019 | Prague, Czech Republic
Charles A Fisher
Fisher Wallace Laboratories, USA
Posters & Accepted Abstracts : J Psychol Cognition
Abstract:
Cranial electrotherapy stimulation (CES) has been shown to produce improvements for insomnia, depression, and anxiety among individuals afflicted with these conditions both with and without primary substance abuse dependence. This report presents findings from a retrospective chart review examining the impact of CES on the retention rates of newly abstinent substance dependent individuals in community-based residential treatment. Clients who received CES sessions during their first month in residential treatment exhibited better retention rates during the first 30 days, as well as at 60 and 90 days in treatment, compared to clients who did not receive CES. Sessions were well tolerated, and clients reported improved sleep and reduced stress.
Biography:
Charles A Fisher is a founder of Fisher Wallace Laboratories which is working to improve the awareness of cranial electrotherapy stimulation in the medical community and to reduce dependencies on medications. A drug-free device available through prescription from any health practitioner licensed for electrotherapy in the United States.
E-mail: chip@fisherwallace.com
PDF HTML